COMPOUND

Compounds / Bioregulators

Cardiogen

Cardiogen (Ala-Glu-Asp-Arg / AEDR Tetrapeptide)

Bioregulators SubQ · Oral Not FDA approved

Khavinson family bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Synthetic tetrapeptide researched as a cardioprotective agent in preclinical models. Most efficacy data is from one Russian lab; independent Western replication is essentially absent. No human cardiac biomarker outcome data.

At a glance

Routes
SubQ · Oral
Vial sizes
20 mg
Evidence base
2 studies 2 preclinical

Mechanism

Per the Khavinson 'short-peptide bioregulator' hypothesis, AEDR is proposed to bind histone proteins H1, H2b, H3, H4 at N-terminal peptide-binding motifs, increasing transcriptional accessibility of cardiac-specific gene promoters. Mechanism is contested in mainstream pharmacology because tetrapeptides are normally degraded in serum within minutes. Reported preclinical effects: three-fold mortality reduction after experimental cardiac injury with activation of cytoskeletal/nuclear matrix protein synthesis cited as mechanism; AEDR induces cardiomyocyte-specific transcription factor expression in cell cultures. Stimulation of cardiomyocyte proliferation and suppression of p53-mediated apoptosis post-injury (Khavinson group single-lab data).

Dosing

No standardized human dosing has been established. Every catalogued study for Cardiogen is preclinical or a literature review. Amounts used in animal models do not translate directly to humans.

Published evidence

  1. Animal in vivo 2010

    Cardioprotective activity of peptide AEDR in experimental cardiac injury

    Khavinson VK, Anisimov SV, et al. Bull Exp Biol Med

    Threefold reduction in mortality after experimental cardiac injury in animals receiving AEDR vs control; activation of cytoskeletal protein synthesis cited as mechanism. Single-lab animal data.

  2. In vitro 2014

    Peptide AEDR and cardiomyocyte differentiation in vitro

    Khavinson VK, Lin'kova NS, et al. Bull Exp Biol Med

    AEDR induced cardiomyocyte-specific transcription factor expression in cell cultures.

Reported side effects

Long-term safety unverified outside Russia
Unknown Mild · Khavinson group reports a clean AE profile; very limited human exposure.

Interactions

  • Vesugen Synergy

    Cardiogen targets cardiomyocyte; Vesugen targets endothelium. Complementary cardiovascular axis in Khavinson stack.

Reconstitution and storage

20 mg vial; 2-5 mL BAC water. At 4 mg/mL, 100 mcg = 0.025 mL.

Lyophilized: room temp short-term, refrigerate for >30 days. Reconstituted: refrigerate, use within 30 days.

Open the reconstitution calculator for Cardiogen